Malignancy
Conditions
Interventions
Gold Standard:Pathological diagnosis
Index test:68Ga/18F/99mTc-P137
Sponsors
Nuclear Medicine Department,Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with high suspicion of prostate cancer ((1) Changes in serum PSA values compared with previous ones (when PSA0.35ng/mL, or PSA>4.0ng/mL annual change> 0.75ng/mL); (2) first- and second-degree relatives with a history of prostate cancer; (3) nuclear magnetic resonance PI-RADS score >= 3) or patients with prostate cancer confirmed by biopsy or surgical pathology, PET can be provided /Clinical laboratory test results (blood routine, biochemistry, serum PSA) within one month before CT examination; at least two other imaging examinations including CT, MRI, nuclear medicine, ultrasound and other imaging techniques; can be completed independently an examination; 2. Patients who have been diagnosed with breast cancer, kidney cancer, thyroid cancer, colorectal cancer and other malignant tumors can provide clinical laboratory test results (blood routine, biochemistry) within one month before the PET/CT examination; at least include CT, Two other imaging examinations including MRI, nuclear medicine, ultrasound and other imaging techniques; can complete the examination independently; 3. The test patients can fully understand and voluntarily participate in this trial, and sign the informed consent.
Exclusion criteria
Exclusion criteria: There is a history of other malignant tumors; those who cannot cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Positive Predictive Value;Negative Predictive Value;Accuracy; | — |
Countries
China
Contacts
Public ContactFan Yan
Peking University First Hospital
Outcome results
None listed